Fig. 1From: Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platformVariant calling performances of GeneReader pipeline. Each individual data point was generated from 18 data points (a) NA12878 and (b) AcroMetrix Oncology HotspotBack to article page